nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00209	0.00209	CcSEcCtD
Apraclonidine—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00209	0.00209	CcSEcCtD
Apraclonidine—Infection—Fluorouracil—urinary bladder cancer	0.00209	0.00209	CcSEcCtD
Apraclonidine—Myalgia—Cisplatin—urinary bladder cancer	0.00208	0.00208	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00208	0.00208	CcSEcCtD
Apraclonidine—Skin disorder—Gemcitabine—urinary bladder cancer	0.00207	0.00207	CcSEcCtD
Apraclonidine—Ill-defined disorder—Etoposide—urinary bladder cancer	0.00207	0.00207	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00206	0.00206	CcSEcCtD
Apraclonidine—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00206	0.00206	CcSEcCtD
Apraclonidine—Discomfort—Cisplatin—urinary bladder cancer	0.00205	0.00205	CcSEcCtD
Apraclonidine—Malaise—Etoposide—urinary bladder cancer	0.00202	0.00202	CcSEcCtD
Apraclonidine—Face oedema—Epirubicin—urinary bladder cancer	0.00201	0.00201	CcSEcCtD
Apraclonidine—Abdominal pain—Thiotepa—urinary bladder cancer	0.00201	0.00201	CcSEcCtD
Apraclonidine—Oedema—Cisplatin—urinary bladder cancer	0.00199	0.00199	CcSEcCtD
Apraclonidine—Infection—Cisplatin—urinary bladder cancer	0.00198	0.00198	CcSEcCtD
Apraclonidine—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00195	0.00195	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.00195	0.00195	CcSEcCtD
Apraclonidine—Skin disorder—Cisplatin—urinary bladder cancer	0.00193	0.00193	CcSEcCtD
Apraclonidine—Insomnia—Gemcitabine—urinary bladder cancer	0.00193	0.00193	CcSEcCtD
Apraclonidine—Asthma—Methotrexate—urinary bladder cancer	0.00192	0.00192	CcSEcCtD
Apraclonidine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00192	0.00192	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00191	0.00191	CcSEcCtD
Apraclonidine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.0019	0.0019	CcSEcCtD
Apraclonidine—Chest pain—Etoposide—urinary bladder cancer	0.0019	0.0019	CcSEcCtD
Apraclonidine—Insomnia—Fluorouracil—urinary bladder cancer	0.0019	0.0019	CcSEcCtD
Apraclonidine—Somnolence—Gemcitabine—urinary bladder cancer	0.0019	0.0019	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00189	0.00189	CcSEcCtD
Apraclonidine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00189	0.00189	CcSEcCtD
Apraclonidine—Discomfort—Etoposide—urinary bladder cancer	0.00188	0.00188	CcSEcCtD
Apraclonidine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00187	0.00187	CcSEcCtD
Apraclonidine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00187	0.00187	CcSEcCtD
Apraclonidine—Somnolence—Fluorouracil—urinary bladder cancer	0.00187	0.00187	CcSEcCtD
Apraclonidine—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.00186	0.00186	CcSEcCtD
Apraclonidine—Face oedema—Doxorubicin—urinary bladder cancer	0.00186	0.00186	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00184	0.00184	CcSEcCtD
Apraclonidine—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.00184	0.00184	CcSEcCtD
Apraclonidine—Fatigue—Gemcitabine—urinary bladder cancer	0.00184	0.00184	CcSEcCtD
Apraclonidine—Pain—Gemcitabine—urinary bladder cancer	0.00183	0.00183	CcSEcCtD
Apraclonidine—Constipation—Gemcitabine—urinary bladder cancer	0.00183	0.00183	CcSEcCtD
Apraclonidine—Asthenia—Thiotepa—urinary bladder cancer	0.00182	0.00182	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00181	0.00181	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00181	0.00181	CcSEcCtD
Apraclonidine—Infection—Etoposide—urinary bladder cancer	0.00181	0.00181	CcSEcCtD
Apraclonidine—Asthma—Epirubicin—urinary bladder cancer	0.0018	0.0018	CcSEcCtD
Apraclonidine—Pruritus—Thiotepa—urinary bladder cancer	0.0018	0.0018	CcSEcCtD
Apraclonidine—Pain—Fluorouracil—urinary bladder cancer	0.0018	0.0018	CcSEcCtD
Apraclonidine—Paraesthesia—Cisplatin—urinary bladder cancer	0.00179	0.00179	CcSEcCtD
Apraclonidine—Dyspnoea—Cisplatin—urinary bladder cancer	0.00178	0.00178	CcSEcCtD
Apraclonidine—Skin disorder—Etoposide—urinary bladder cancer	0.00177	0.00177	CcSEcCtD
Apraclonidine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00176	0.00176	CcSEcCtD
Apraclonidine—Diarrhoea—Thiotepa—urinary bladder cancer	0.00174	0.00174	CcSEcCtD
Apraclonidine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00173	0.00173	CcSEcCtD
Apraclonidine—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.00172	0.00172	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00172	0.00172	CcSEcCtD
Apraclonidine—Infestation NOS—Methotrexate—urinary bladder cancer	0.00171	0.00171	CcSEcCtD
Apraclonidine—Infestation—Methotrexate—urinary bladder cancer	0.00171	0.00171	CcSEcCtD
Apraclonidine—Pain—Cisplatin—urinary bladder cancer	0.0017	0.0017	CcSEcCtD
Apraclonidine—Dizziness—Thiotepa—urinary bladder cancer	0.00168	0.00168	CcSEcCtD
Apraclonidine—Conjunctivitis—Methotrexate—urinary bladder cancer	0.00167	0.00167	CcSEcCtD
Apraclonidine—Asthma—Doxorubicin—urinary bladder cancer	0.00166	0.00166	CcSEcCtD
Apraclonidine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00164	0.00164	CcSEcCtD
Apraclonidine—Paraesthesia—Etoposide—urinary bladder cancer	0.00164	0.00164	CcSEcCtD
Apraclonidine—Dyspnoea—Etoposide—urinary bladder cancer	0.00163	0.00163	CcSEcCtD
Apraclonidine—Somnolence—Etoposide—urinary bladder cancer	0.00162	0.00162	CcSEcCtD
Apraclonidine—Vomiting—Thiotepa—urinary bladder cancer	0.00161	0.00161	CcSEcCtD
Apraclonidine—Infestation NOS—Epirubicin—urinary bladder cancer	0.0016	0.0016	CcSEcCtD
Apraclonidine—Infestation—Epirubicin—urinary bladder cancer	0.0016	0.0016	CcSEcCtD
Apraclonidine—Dermatitis—Thiotepa—urinary bladder cancer	0.0016	0.0016	CcSEcCtD
Apraclonidine—Headache—Thiotepa—urinary bladder cancer	0.00159	0.00159	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00157	0.00157	CcSEcCtD
Apraclonidine—Fatigue—Etoposide—urinary bladder cancer	0.00157	0.00157	CcSEcCtD
Apraclonidine—Pain—Etoposide—urinary bladder cancer	0.00156	0.00156	CcSEcCtD
Apraclonidine—Constipation—Etoposide—urinary bladder cancer	0.00156	0.00156	CcSEcCtD
Apraclonidine—Conjunctivitis—Epirubicin—urinary bladder cancer	0.00156	0.00156	CcSEcCtD
Apraclonidine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00155	0.00155	CcSEcCtD
Apraclonidine—Haemorrhage—Methotrexate—urinary bladder cancer	0.00154	0.00154	CcSEcCtD
Apraclonidine—Asthenia—Gemcitabine—urinary bladder cancer	0.00153	0.00153	CcSEcCtD
Apraclonidine—Pharyngitis—Methotrexate—urinary bladder cancer	0.00153	0.00153	CcSEcCtD
Apraclonidine—Pruritus—Gemcitabine—urinary bladder cancer	0.00151	0.00151	CcSEcCtD
Apraclonidine—Nausea—Thiotepa—urinary bladder cancer	0.00151	0.00151	CcSEcCtD
Apraclonidine—Feeling abnormal—Etoposide—urinary bladder cancer	0.0015	0.0015	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00149	0.00149	CcSEcCtD
Apraclonidine—Pruritus—Fluorouracil—urinary bladder cancer	0.00149	0.00149	CcSEcCtD
Apraclonidine—Infestation—Doxorubicin—urinary bladder cancer	0.00148	0.00148	CcSEcCtD
Apraclonidine—Infestation NOS—Doxorubicin—urinary bladder cancer	0.00148	0.00148	CcSEcCtD
Apraclonidine—Visual impairment—Methotrexate—urinary bladder cancer	0.00148	0.00148	CcSEcCtD
Apraclonidine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00147	0.00147	CcSEcCtD
Apraclonidine—Bradycardia—Epirubicin—urinary bladder cancer	0.00147	0.00147	CcSEcCtD
Apraclonidine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00146	0.00146	CcSEcCtD
Apraclonidine—Rhinitis—Epirubicin—urinary bladder cancer	0.00144	0.00144	CcSEcCtD
Apraclonidine—Abdominal pain—Etoposide—urinary bladder cancer	0.00144	0.00144	CcSEcCtD
Apraclonidine—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.00144	0.00144	CcSEcCtD
Apraclonidine—Haemorrhage—Epirubicin—urinary bladder cancer	0.00144	0.00144	CcSEcCtD
Apraclonidine—Eye disorder—Methotrexate—urinary bladder cancer	0.00144	0.00144	CcSEcCtD
Apraclonidine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00144	0.00144	CcSEcCtD
Apraclonidine—Asthenia—Cisplatin—urinary bladder cancer	0.00143	0.00143	CcSEcCtD
Apraclonidine—Pharyngitis—Epirubicin—urinary bladder cancer	0.00143	0.00143	CcSEcCtD
Apraclonidine—Oedema peripheral—Epirubicin—urinary bladder cancer	0.00142	0.00142	CcSEcCtD
Apraclonidine—Angiopathy—Methotrexate—urinary bladder cancer	0.0014	0.0014	CcSEcCtD
Apraclonidine—Dizziness—Fluorouracil—urinary bladder cancer	0.00139	0.00139	CcSEcCtD
Apraclonidine—Visual impairment—Epirubicin—urinary bladder cancer	0.00139	0.00139	CcSEcCtD
Apraclonidine—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.00139	0.00139	CcSEcCtD
Apraclonidine—Diarrhoea—Cisplatin—urinary bladder cancer	0.00136	0.00136	CcSEcCtD
Apraclonidine—Vomiting—Gemcitabine—urinary bladder cancer	0.00136	0.00136	CcSEcCtD
Apraclonidine—Bradycardia—Doxorubicin—urinary bladder cancer	0.00136	0.00136	CcSEcCtD
Apraclonidine—Mental disorder—Methotrexate—urinary bladder cancer	0.00135	0.00135	CcSEcCtD
Apraclonidine—Dermatitis—Gemcitabine—urinary bladder cancer	0.00135	0.00135	CcSEcCtD
Apraclonidine—Eye disorder—Epirubicin—urinary bladder cancer	0.00135	0.00135	CcSEcCtD
Apraclonidine—Hypersensitivity—Etoposide—urinary bladder cancer	0.00134	0.00134	CcSEcCtD
Apraclonidine—Erythema—Methotrexate—urinary bladder cancer	0.00134	0.00134	CcSEcCtD
Apraclonidine—Headache—Gemcitabine—urinary bladder cancer	0.00134	0.00134	CcSEcCtD
Apraclonidine—Vomiting—Fluorouracil—urinary bladder cancer	0.00134	0.00134	CcSEcCtD
Apraclonidine—Rhinitis—Doxorubicin—urinary bladder cancer	0.00134	0.00134	CcSEcCtD
Apraclonidine—Haemorrhage—Doxorubicin—urinary bladder cancer	0.00133	0.00133	CcSEcCtD
Apraclonidine—Dermatitis—Fluorouracil—urinary bladder cancer	0.00132	0.00132	CcSEcCtD
Apraclonidine—Pharyngitis—Doxorubicin—urinary bladder cancer	0.00132	0.00132	CcSEcCtD
Apraclonidine—Headache—Fluorouracil—urinary bladder cancer	0.00132	0.00132	CcSEcCtD
Apraclonidine—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.00131	0.00131	CcSEcCtD
Apraclonidine—Dysgeusia—Methotrexate—urinary bladder cancer	0.00131	0.00131	CcSEcCtD
Apraclonidine—Asthenia—Etoposide—urinary bladder cancer	0.00131	0.00131	CcSEcCtD
Apraclonidine—Angiopathy—Epirubicin—urinary bladder cancer	0.00131	0.00131	CcSEcCtD
Apraclonidine—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.0013	0.0013	CcSEcCtD
Apraclonidine—Pruritus—Etoposide—urinary bladder cancer	0.00129	0.00129	CcSEcCtD
Apraclonidine—Arrhythmia—Epirubicin—urinary bladder cancer	0.00129	0.00129	CcSEcCtD
Apraclonidine—Visual impairment—Doxorubicin—urinary bladder cancer	0.00128	0.00128	CcSEcCtD
Apraclonidine—Nausea—Gemcitabine—urinary bladder cancer	0.00127	0.00127	CcSEcCtD
Apraclonidine—Vomiting—Cisplatin—urinary bladder cancer	0.00127	0.00127	CcSEcCtD
Apraclonidine—Vision blurred—Methotrexate—urinary bladder cancer	0.00126	0.00126	CcSEcCtD
Apraclonidine—Mental disorder—Epirubicin—urinary bladder cancer	0.00126	0.00126	CcSEcCtD
Apraclonidine—Dermatitis—Cisplatin—urinary bladder cancer	0.00125	0.00125	CcSEcCtD
Apraclonidine—Erythema—Epirubicin—urinary bladder cancer	0.00125	0.00125	CcSEcCtD
Apraclonidine—Diarrhoea—Etoposide—urinary bladder cancer	0.00125	0.00125	CcSEcCtD
Apraclonidine—Nausea—Fluorouracil—urinary bladder cancer	0.00125	0.00125	CcSEcCtD
Apraclonidine—Eye disorder—Doxorubicin—urinary bladder cancer	0.00124	0.00124	CcSEcCtD
Apraclonidine—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00124	0.00124	CcSEcCtD
Apraclonidine—Tension—Epirubicin—urinary bladder cancer	0.00123	0.00123	CcSEcCtD
Apraclonidine—Dysgeusia—Epirubicin—urinary bladder cancer	0.00123	0.00123	CcSEcCtD
Apraclonidine—Nervousness—Epirubicin—urinary bladder cancer	0.00122	0.00122	CcSEcCtD
Apraclonidine—Angiopathy—Doxorubicin—urinary bladder cancer	0.00121	0.00121	CcSEcCtD
Apraclonidine—Malaise—Methotrexate—urinary bladder cancer	0.00121	0.00121	CcSEcCtD
Apraclonidine—Dizziness—Etoposide—urinary bladder cancer	0.00121	0.00121	CcSEcCtD
Apraclonidine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.0012	0.0012	CcSEcCtD
Apraclonidine—Arrhythmia—Doxorubicin—urinary bladder cancer	0.00119	0.00119	CcSEcCtD
Apraclonidine—Nausea—Cisplatin—urinary bladder cancer	0.00118	0.00118	CcSEcCtD
Apraclonidine—Vision blurred—Epirubicin—urinary bladder cancer	0.00118	0.00118	CcSEcCtD
Apraclonidine—Mental disorder—Doxorubicin—urinary bladder cancer	0.00117	0.00117	CcSEcCtD
Apraclonidine—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.00116	0.00116	CcSEcCtD
Apraclonidine—Vomiting—Etoposide—urinary bladder cancer	0.00116	0.00116	CcSEcCtD
Apraclonidine—Erythema—Doxorubicin—urinary bladder cancer	0.00116	0.00116	CcSEcCtD
Apraclonidine—Dermatitis—Etoposide—urinary bladder cancer	0.00115	0.00115	CcSEcCtD
Apraclonidine—Headache—Etoposide—urinary bladder cancer	0.00114	0.00114	CcSEcCtD
Apraclonidine—Chest pain—Methotrexate—urinary bladder cancer	0.00114	0.00114	CcSEcCtD
Apraclonidine—Myalgia—Methotrexate—urinary bladder cancer	0.00114	0.00114	CcSEcCtD
Apraclonidine—Tension—Doxorubicin—urinary bladder cancer	0.00114	0.00114	CcSEcCtD
Apraclonidine—Dysgeusia—Doxorubicin—urinary bladder cancer	0.00114	0.00114	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.00113	0.00113	CcSEcCtD
Apraclonidine—Malaise—Epirubicin—urinary bladder cancer	0.00113	0.00113	CcSEcCtD
Apraclonidine—Discomfort—Methotrexate—urinary bladder cancer	0.00113	0.00113	CcSEcCtD
Apraclonidine—Nervousness—Doxorubicin—urinary bladder cancer	0.00113	0.00113	CcSEcCtD
Apraclonidine—Syncope—Epirubicin—urinary bladder cancer	0.00112	0.00112	CcSEcCtD
Apraclonidine—Palpitations—Epirubicin—urinary bladder cancer	0.00111	0.00111	CcSEcCtD
Apraclonidine—Vision blurred—Doxorubicin—urinary bladder cancer	0.00109	0.00109	CcSEcCtD
Apraclonidine—Infection—Methotrexate—urinary bladder cancer	0.00109	0.00109	CcSEcCtD
Apraclonidine—Nausea—Etoposide—urinary bladder cancer	0.00108	0.00108	CcSEcCtD
Apraclonidine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.00108	0.00108	CcSEcCtD
Apraclonidine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.00107	0.00107	CcSEcCtD
Apraclonidine—Chest pain—Epirubicin—urinary bladder cancer	0.00107	0.00107	CcSEcCtD
Apraclonidine—Myalgia—Epirubicin—urinary bladder cancer	0.00107	0.00107	CcSEcCtD
Apraclonidine—Skin disorder—Methotrexate—urinary bladder cancer	0.00106	0.00106	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.00106	0.00106	CcSEcCtD
Apraclonidine—Discomfort—Epirubicin—urinary bladder cancer	0.00105	0.00105	CcSEcCtD
Apraclonidine—Malaise—Doxorubicin—urinary bladder cancer	0.00105	0.00105	CcSEcCtD
Apraclonidine—Dry mouth—Epirubicin—urinary bladder cancer	0.00104	0.00104	CcSEcCtD
Apraclonidine—Syncope—Doxorubicin—urinary bladder cancer	0.00104	0.00104	CcSEcCtD
Apraclonidine—Palpitations—Doxorubicin—urinary bladder cancer	0.00102	0.00102	CcSEcCtD
Apraclonidine—Oedema—Epirubicin—urinary bladder cancer	0.00102	0.00102	CcSEcCtD
Apraclonidine—Infection—Epirubicin—urinary bladder cancer	0.00102	0.00102	CcSEcCtD
Apraclonidine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.001	0.001	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000995	0.000995	CcSEcCtD
Apraclonidine—Skin disorder—Epirubicin—urinary bladder cancer	0.000993	0.000993	CcSEcCtD
Apraclonidine—Insomnia—Methotrexate—urinary bladder cancer	0.000988	0.000988	CcSEcCtD
Apraclonidine—Chest pain—Doxorubicin—urinary bladder cancer	0.000987	0.000987	CcSEcCtD
Apraclonidine—Myalgia—Doxorubicin—urinary bladder cancer	0.000987	0.000987	CcSEcCtD
Apraclonidine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000981	0.000981	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.00098	0.00098	CcSEcCtD
Apraclonidine—Discomfort—Doxorubicin—urinary bladder cancer	0.000975	0.000975	CcSEcCtD
Apraclonidine—Dyspnoea—Methotrexate—urinary bladder cancer	0.000974	0.000974	CcSEcCtD
Apraclonidine—Somnolence—Methotrexate—urinary bladder cancer	0.000971	0.000971	CcSEcCtD
Apraclonidine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000965	0.000965	CcSEcCtD
Apraclonidine—Oedema—Doxorubicin—urinary bladder cancer	0.000946	0.000946	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000943	0.000943	CcSEcCtD
Apraclonidine—Fatigue—Methotrexate—urinary bladder cancer	0.000942	0.000942	CcSEcCtD
Apraclonidine—Infection—Doxorubicin—urinary bladder cancer	0.00094	0.00094	CcSEcCtD
Apraclonidine—Pain—Methotrexate—urinary bladder cancer	0.000934	0.000934	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000932	0.000932	CcSEcCtD
Apraclonidine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000928	0.000928	CcSEcCtD
Apraclonidine—Insomnia—Epirubicin—urinary bladder cancer	0.000925	0.000925	CcSEcCtD
Apraclonidine—Skin disorder—Doxorubicin—urinary bladder cancer	0.000919	0.000919	CcSEcCtD
Apraclonidine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000918	0.000918	CcSEcCtD
Apraclonidine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000912	0.000912	CcSEcCtD
Apraclonidine—Somnolence—Epirubicin—urinary bladder cancer	0.000909	0.000909	CcSEcCtD
Apraclonidine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.0009	0.0009	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000893	0.000893	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000883	0.000883	CcSEcCtD
Apraclonidine—Fatigue—Epirubicin—urinary bladder cancer	0.000882	0.000882	CcSEcCtD
Apraclonidine—Constipation—Epirubicin—urinary bladder cancer	0.000874	0.000874	CcSEcCtD
Apraclonidine—Pain—Epirubicin—urinary bladder cancer	0.000874	0.000874	CcSEcCtD
Apraclonidine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000864	0.000864	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000862	0.000862	CcSEcCtD
Apraclonidine—Insomnia—Doxorubicin—urinary bladder cancer	0.000856	0.000856	CcSEcCtD
Apraclonidine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.00085	0.00085	CcSEcCtD
Apraclonidine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000843	0.000843	CcSEcCtD
Apraclonidine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000843	0.000843	CcSEcCtD
Apraclonidine—Somnolence—Doxorubicin—urinary bladder cancer	0.000841	0.000841	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000836	0.000836	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000817	0.000817	CcSEcCtD
Apraclonidine—Fatigue—Doxorubicin—urinary bladder cancer	0.000816	0.000816	CcSEcCtD
Apraclonidine—Constipation—Doxorubicin—urinary bladder cancer	0.000809	0.000809	CcSEcCtD
Apraclonidine—Pain—Doxorubicin—urinary bladder cancer	0.000809	0.000809	CcSEcCtD
Apraclonidine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000808	0.000808	CcSEcCtD
Apraclonidine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000805	0.000805	CcSEcCtD
Apraclonidine—Asthenia—Methotrexate—urinary bladder cancer	0.000784	0.000784	CcSEcCtD
Apraclonidine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.00078	0.00078	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000774	0.000774	CcSEcCtD
Apraclonidine—Pruritus—Methotrexate—urinary bladder cancer	0.000773	0.000773	CcSEcCtD
Apraclonidine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000753	0.000753	CcSEcCtD
Apraclonidine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000748	0.000748	CcSEcCtD
Apraclonidine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000748	0.000748	CcSEcCtD
Apraclonidine—Asthenia—Epirubicin—urinary bladder cancer	0.000734	0.000734	CcSEcCtD
Apraclonidine—Pruritus—Epirubicin—urinary bladder cancer	0.000723	0.000723	CcSEcCtD
Apraclonidine—Dizziness—Methotrexate—urinary bladder cancer	0.000723	0.000723	CcSEcCtD
Apraclonidine—Diarrhoea—Epirubicin—urinary bladder cancer	0.0007	0.0007	CcSEcCtD
Apraclonidine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000697	0.000697	CcSEcCtD
Apraclonidine—Vomiting—Methotrexate—urinary bladder cancer	0.000695	0.000695	CcSEcCtD
Apraclonidine—Dermatitis—Methotrexate—urinary bladder cancer	0.000688	0.000688	CcSEcCtD
Apraclonidine—Headache—Methotrexate—urinary bladder cancer	0.000684	0.000684	CcSEcCtD
Apraclonidine—Asthenia—Doxorubicin—urinary bladder cancer	0.000679	0.000679	CcSEcCtD
Apraclonidine—Dizziness—Epirubicin—urinary bladder cancer	0.000676	0.000676	CcSEcCtD
Apraclonidine—Pruritus—Doxorubicin—urinary bladder cancer	0.000669	0.000669	CcSEcCtD
Apraclonidine—Vomiting—Epirubicin—urinary bladder cancer	0.00065	0.00065	CcSEcCtD
Apraclonidine—Nausea—Methotrexate—urinary bladder cancer	0.000649	0.000649	CcSEcCtD
Apraclonidine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000647	0.000647	CcSEcCtD
Apraclonidine—Dermatitis—Epirubicin—urinary bladder cancer	0.000644	0.000644	CcSEcCtD
Apraclonidine—Headache—Epirubicin—urinary bladder cancer	0.000641	0.000641	CcSEcCtD
Apraclonidine—Dizziness—Doxorubicin—urinary bladder cancer	0.000626	0.000626	CcSEcCtD
Apraclonidine—Nausea—Epirubicin—urinary bladder cancer	0.000607	0.000607	CcSEcCtD
Apraclonidine—Vomiting—Doxorubicin—urinary bladder cancer	0.000602	0.000602	CcSEcCtD
Apraclonidine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000596	0.000596	CcSEcCtD
Apraclonidine—Headache—Doxorubicin—urinary bladder cancer	0.000593	0.000593	CcSEcCtD
Apraclonidine—Nausea—Doxorubicin—urinary bladder cancer	0.000562	0.000562	CcSEcCtD
